

DCAT TOP Industry NEWS

*BUSY WEEK? Here are the
TOP INDUSTRY NEWS stories
you might have missed, as
selected by DCAT Editorial
Director Patricia Van Arnum.*



DCAT

AFTER THE SHOW

A Member Company Networking Event

BARCELONA 2016

WEDNESDAY OCTOBER 5TH • 6:00 PM – 8:30 PM • CASA LLOTJA DE MAR

1. [Bayer, Monsanto Agree to Merge in \\$66 Billion Deal](#)

In its first-large scale acquisition since becoming a pure-play life-sciences company, Bayer has agreed to acquire Monsanto, an agrochemical and seed company in a deal valued at approximately \$66 billion. The merger agreement has been unanimously approved by the boards of both companies and ends a four-month effort by Bayer to come to terms with Monsanto for the acquisition.

[Read More](#)

2. [Allergan to Acquire Vitae Pharmaceuticals for \\$639 Million](#)

Allergan has agreed to acquire Vitae Pharmaceuticals, a clinical-stage biotechnology company for a total transaction value of approximately \$639 million. The acquisition will strengthen Allergan's dermatology product pipeline, which includes a Phase II oral treatment for psoriasis and other autoimmune disorders. [Read More](#)

3. [Perrigo Shareholder Seeks Change for Improved Performance](#)

Starboard Value, an investment firm with a 4.6% stake in Perrigo, a generic, over-the-counter and specialty pharmaceutical company, has issued a letter to Perrigo CEO, John Hendrickson, and Perrigo's board of director to begin what it termed a "constructive engagement" to drive value creation for the company's shareholders. The firm took issue with the company's rejection of Mylan's \$26-billion takeover bid last year and subsequent financial and stock performance. [Read More](#)

4. [Horizon Pharma to Acquire Raptor in Deal Valued at \\$800 Million](#)

Horizon Pharma, a biopharmaceutical company based in Dublin, Ireland, has agreed to acquire Raptor Pharmaceutical, a Novato, California-based biopharmaceutical company, in a deal value of approximately \$800 million. The acquisition gives Horizon Pharma global rights to Raptor's Procysbi (cysteamine bitartrate), a drug to treat a rare metabolic disorder. [Read More](#)

5. [Sanofi, Google's Verily Launch Diabetes JV](#)

In an example of pharmaceutical companies going "beyond the pill," Sanofi and Verily Life Sciences (formerly Google Life Sciences) have launched Onduo, a joint venture created through Sanofi and Verily's diabetes-focused collaboration. Onduo will focus on developing solutions that combine devices, software, medicine, and professional care for disease management. [Read More](#)

6. [GSK Divests Anesthesia Assets to Aspen](#)

GlaxoSmithKline plans to divest its anesthesia portfolio to Aspen Pharma, based in KwaZulu-Natal, South Africa, for £180 million (\$240 million) plus milestones of up to £100 million (\$133 million). In addition to this divestment, GSK and Aspen have entered into parallel agreements to terminate their

collaboration in Sub-Saharan Africa and for Aspen to exercise its option to acquire GSK's remaining thrombosis business in certain other markets. [Read More](#)

7. [Catalent To Acquire Pharmatek Laboratories](#)

Catalent, through its wholly owned subsidiary, Catalent Pharma Solutions, has agreed, to acquire Pharmatek Laboratories, a CDMO based in San Diego, California. Pharmatek provides dosage form development and clinical-scale cGMP manufacturing of oral, injectable, and topical products, including for high-potency drugs. [Read More](#)

8. [Novo Nordisk Voluntarily Recalls Select Batches of Diabetes Kit](#)

Novo Nordisk has implemented a voluntary recall of six batches of the GlucaGen HypoKit (glucagon [rDNA origin] for injection) in the US due to two customer complaints from the UK and Portugal involving detached needles on the syringe with sterile water for injection. It is estimated that out of the 71,215 pens being recalled, four pens could be defective. [Read More](#)

9. [US Gov't Awards Protein Sciences Vaccine Pact in \\$610 Million Deal](#)

The Biomedical Advanced Research and Development Authority (BARDA), a division of the US Department of Health and Human Services, has awarded Protein Sciences Corporation, a Meriden, Connecticut-based company, a contract for producing vaccines for pandemic influenza and influenza strains with pandemic potential. The contract is valued up to \$610 million through 2021 if BARDA exercises all options. [Read More](#)

10. [J&J's Ebola Vaccine Candidate Advances](#)

Janssen Vaccines & Prevention, part of Johnson & Johnson, has completed a submission to the World Health Organization for Emergency Use Assessment and Listing (EUAL) for its investigational preventive Ebola prime-boost vaccine regimen. The EUAL is a special procedure that can be implemented when there is an outbreak of a disease with high rates of morbidity or mortality and a lack of treatment or prevention options. [Read More](#)

****Upcoming DCAT Event****

[DCAT After the Show](#)

Don't miss DCAT's inaugural networking event following CPhI Worldwide in Barcelona on Wednesday, October 5th from 6:00 PM to 8:30 PM at the beautiful Casa Llotja de Mar. Located just steps away from the Gothic Quarter and Port of Barcelona, this event offers the perfect opportunity to utilize that time between the tradeshow and your late-night dinner plans to catch up with colleagues and establish valuable industry connections.

Registration for this event is now open. The reception is \$79.00 USD per person, and includes food and beverage, and transportation from the show to Casa Llotja de Mar, compliments of ACIC Fine Chemicals, Inc. Further event information and available branding opportunities may be found [here](#).

*The DCAT organization is happy to provide this service to its members each Friday.
Have a great weekend!*

[About Top Industry News](#)

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



www.dcat.org

Drug, Chemical, & Associated Technologies Association, One Union Street,
Suite 208, Robbinsville, NJ 08691

SafeUnsubscribe™ {recipient's email}

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by dcatnews@dcat.org